In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions.

In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions. by Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI and Mendes RE published in Microb. Drug Resist., 2017; 23 (6): 718-726